TY - JOUR
T1 - Polylactic acid for visualizing the vitreous body during vitrectomy
AU - Yamashita, Toshifumi
AU - Sakamoto, Taiji
AU - Yamakiri, Keita
AU - Miura, Muneki
AU - Enaida, Hiroshi
AU - Ueno, Akifumi
AU - Atsumi, Ikuyo
AU - Matsuhisa, Keucht
AU - Sakamoto, Yuji
AU - Kida, Tetsuo
AU - Ishibashi, Tatsuro
PY - 2007/7
Y1 - 2007/7
N2 - PURPOSE. To investigate the possibility of using polylactic acid (PLA) as a surgical adjuvant for visualizing the vitreous body during vitrectomy. METHODS. After a core vitrectomy, 1 mL of PLA suspension was injected into the rabbit vitreous in two groups: group A, 2.5% PLA (n = 5), and group B, 1% PLA (n = 9). Vehicle injection instead of PLA was used as a control (group C, n = 5). The clinical signs and electroretinogram (ERG) were evaluated for 28 days, and histologic findings were evaluated on day 28. Next, intraocular pressure (JOP) after intracameral injection of a PLA suspension was evaluated in the rabbits (n = 6). Last, the visualization of the vitreous body by PLA suspension was evaluated during vitrectomy in monkey eyes (n = 4). RESULTS. The white granules of PLA disappeared from the vitreous cavity in 10 eyes within 3 weeks; however, a small amount of PLA remained in four eyes for 4 weeks. Mild inflammation of the anterior chamber was observed in one eye in group B and 1 eye in group C. No cataract or retinal hemorrhage was found in any eyes. The amplitude of ERG on each time point did not differ between the groups. IOP remained within normal range except for the initial spike. Retinal structure was well preserved histologically. During vitrectomy in monkey eyes, the vitreous body was well visualized, and the posterior vitreous separation was performed easily and safely. CONCLUSIONS. PLA can be a new surgical adjuvant to visualize the vitreous body during vitrectomy.
AB - PURPOSE. To investigate the possibility of using polylactic acid (PLA) as a surgical adjuvant for visualizing the vitreous body during vitrectomy. METHODS. After a core vitrectomy, 1 mL of PLA suspension was injected into the rabbit vitreous in two groups: group A, 2.5% PLA (n = 5), and group B, 1% PLA (n = 9). Vehicle injection instead of PLA was used as a control (group C, n = 5). The clinical signs and electroretinogram (ERG) were evaluated for 28 days, and histologic findings were evaluated on day 28. Next, intraocular pressure (JOP) after intracameral injection of a PLA suspension was evaluated in the rabbits (n = 6). Last, the visualization of the vitreous body by PLA suspension was evaluated during vitrectomy in monkey eyes (n = 4). RESULTS. The white granules of PLA disappeared from the vitreous cavity in 10 eyes within 3 weeks; however, a small amount of PLA remained in four eyes for 4 weeks. Mild inflammation of the anterior chamber was observed in one eye in group B and 1 eye in group C. No cataract or retinal hemorrhage was found in any eyes. The amplitude of ERG on each time point did not differ between the groups. IOP remained within normal range except for the initial spike. Retinal structure was well preserved histologically. During vitrectomy in monkey eyes, the vitreous body was well visualized, and the posterior vitreous separation was performed easily and safely. CONCLUSIONS. PLA can be a new surgical adjuvant to visualize the vitreous body during vitrectomy.
UR - http://www.scopus.com/inward/record.url?scp=34548075340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548075340&partnerID=8YFLogxK
U2 - 10.1167/iovs.06-1020
DO - 10.1167/iovs.06-1020
M3 - Article
C2 - 17591899
AN - SCOPUS:34548075340
VL - 48
SP - 3277
EP - 3282
JO - Investigative Ophthalmology
JF - Investigative Ophthalmology
SN - 0146-0404
IS - 7
ER -